Exicure (XCUR) said its subsidiary, GPCR Therapeutics USA, dosed the 19th patient in an ongoing phase 2 clinical trial of a small molecule inhibitor in multiple myeloma patients undergoing autologous stem cell transplant.
The trial is expected to finish patient recruitment at the end of April.
The study is a multi-center trial evaluating the safety and efficacy of the CXCR4 inhibitor, GPC-100 (burixafor), and propranolol in combination with G-CSF, the company said late Monday.
It said the study's preliminary results are encouraging as 100% of patients achieved the primary endpoint of successful stem cell mobilization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.